Navigation Links
Clearance of hepatitis C viral infection after liver transplantation
Date:8/29/2007

Touching stories of living donor transplantation are continuously happening in hospitals. One of these stories is reported recently in the August 14 issue of the World Journal of Gastroenterology because of its shining significance in hepatology. This article is going to bring comfort to many families.

It is about a desperate patient brought to Dr. Tatsuki Ichikawa in the Nagasaki University Hospital, Japan in 2004. This patient was quite a challenge for Dr Ichikawa. She was 60 years old with liver cirrhosis (LC) and liver cancer caused by hepatitis C virus (HCV); she had been diagnosed diabetic since 1995; and previous chemotherapies aiming to remove cancer did not bring any satisfactory result.

To free the patient from the severely damaged liver, liver transplantation (LT) was considered by Dr. Ichikawa when a loving daughter of the patient decided to donate part of her liver to her mother. However, one possibility that concerned Dr. Ichikawa most was that the explanted liver would get re-infected and progress rapidly to LC, since previous data indicated that complete clearance of HCV is the prerequisite for patients to have a good outcome. To minimize this possibility, patients were traditionally treated with interferon (IFN) and/or ribavirin before LT.

Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, PEGylated IFN, in the treatment before liver transplantation. PEGylation is a chemical modification incurring higher water-solubility and higher stability to the modified polypeptide medicine. Five weeks after the PEG-IFN treatment, HCV antigen was no longer detectable from the patient serum, but HCV-RNA persisted. Even after the long treatment for 18 weeks, HCV RNA was still detectable. Since the complete clearance of HCV RNA seemed impossible, the liver transplantation was performed.

Unexpectedly and excitingly, clearance of HCV RNA was achieved just one month after the successful liver transplantation and HCV was never detected in this patient thereafter. Thus, this is the first reported case in which a complete recovery from HCV infection was achieved after LT, with a patient who was diagnosed positive in HCV-RNA and negative in HCV core antigen before LT. Dr. Ichikawa suggested that the long acting of PEG-IFN might bring good outcome to similar patients awaiting liver transplantation.

This case no doubt brings promising future for many LC patients. Due to the high percentage of HCV infected population in the world and unavailability of commercial vaccine against HCV, the case reported by Dr Ichikawa surely worth the attention of both doctors and common people.


'/>"/>
Contact: Lixin Zhu
wjg@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
4. UCLA study assesses cost-effectiveness of Hepatitis B drugs
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers
8. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
9. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
10. Researchers create infectious hepatitis C virus in a test tube
11. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... 18, 2017 , ... Executive search firm Slone Partners proudly ... to the advancement of the clinical trials segment. Hosted in Miami, this conference ... planning and management. , As executive talent specialists in the industries central ...
(Date:1/18/2017)... ... 18, 2017 , ... MYOLYN, which creates medical technology for ... 510(k) to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle ... , The submission marks a major milestone for the technology startup. MYOLYN ...
(Date:1/18/2017)... San Francisco, CA (PRWEB) , ... January 18, ... ... delighted to report the publishing of the latest paper by its Science Editor, ... Medical Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October ...
(Date:1/18/2017)... IRVING, Texas , Jan. 18, 2017 /PRNewswire/ ... science, and the Lustgarten Foundation, the largest private ... support a clinical trial evaluating the impact of ... is providing clinical trial enrollment services to identify ... and facilitate communication between treating physicians and study ...
Breaking Biology Technology: